These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 10074589)

  • 1. Management of heparin-induced thrombocytopenia during continuous renal replacement therapy.
    Davenport A
    Am J Kidney Dis; 1998 Oct; 32(4):E3. PubMed ID: 10074589
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Thrombocytopenia due to heparin therapy. Use of danaparoid (Orgaran), 13 monocentric cases under authorization of temporary prescription (ATU)].
    Gindre L; de Maistre E; Perrin A; Lecompte T; Hoffman MA
    Therapie; 1997; 52(6):591-7. PubMed ID: 9734113
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The use of low dose Orgaran in heparin-induced thrombocytopenia associated with in vitro platelet aggregation at higher Orgaran concentrations.
    Hill GR; Hickton C; Henderson S; Patton WN
    Clin Lab Haematol; 1997 Jun; 19(2):155-7. PubMed ID: 9218159
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Value of orgaran in hemodialysis during heparin-induced thrombopenia].
    Lamriben L; Tiberghien F; Delacour JL; Floriot C; Wagschal G; Daoudal P; Ory JP
    Presse Med; 1996 Sep; 25(28):1303. PubMed ID: 8949796
    [No Abstract]   [Full Text] [Related]  

  • 5. [Extracorporeal circulation with danaparoid sodium for valve replacement in thrombocytopenia induced by type II heparin].
    Salmi L; Leroy-Matheron C; LeBesnerais P; Rosanval O; Duvaldestin P; Gouault-Heilmann M
    Ann Fr Anesth Reanim; 2001 Nov; 20(9):799-802. PubMed ID: 11759322
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Orgaran during rotational atherectomy in the setting of heparin-induced thrombocytopenia.
    Hale LP; Smith K; Braden GA; Owen J
    Cathet Cardiovasc Diagn; 1998 Nov; 45(3):318-22. PubMed ID: 9829897
    [TBL] [Abstract][Full Text] [Related]  

  • 7. On the prophylactic and therapeutic use of danaparoid sodium (Orgaran) in patients with heparin-induced thrombocytopenia.
    Schenk JF; Pindur G; Stephan B; Mörsdorf S; Mertzlufft F; Kroll H; Wenzel E; Seyfert UT
    Clin Appl Thromb Hemost; 2003 Jan; 9(1):25-32. PubMed ID: 12643320
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anticoagulation options for patients with heparin-induced thrombocytopenia requiring renal support in the intensive care unit.
    Davenport A
    Contrib Nephrol; 2007; 156():259-66. PubMed ID: 17464135
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Danaparoid (orgaran) for continuous venovenous hemodiafiltration in a patient with heparin-induced thrombocytopenia].
    Christin F; Theissen-Laval O; Loeb JP
    Ann Fr Anesth Reanim; 1998; 17(1):82-3. PubMed ID: 9750692
    [No Abstract]   [Full Text] [Related]  

  • 10. Failure of Orgaran therapy in a patient with a previous heparin-induced thrombocytopenia syndrome.
    Tardy/Poncet B; Mahul P; Beraud AM; Favre JP; Tardy B; Guyotat D
    Br J Haematol; 1995 Aug; 90(4):969-70. PubMed ID: 7669684
    [No Abstract]   [Full Text] [Related]  

  • 11. [Clinical experiences with Danaparoid sodium. Measures to be taken in heparin-induced thrombocytopenia].
    Anaesthesist; 1998 Nov; 47(11 Suppl Massnahmen):1-4. PubMed ID: 9884734
    [No Abstract]   [Full Text] [Related]  

  • 12. Heparin-induced thrombocytopenia type II: successful use of Orgaran (ORG 10172) in intensive care patients.
    Burkhard-Meier U; Söhngen D; Schultheiss HP; Greinacher A; Schwartzkopff B; Vogt M; Heyll A; Schneider W
    Intensive Care Med; 1995 Jun; 21(6):542-3. PubMed ID: 7560499
    [No Abstract]   [Full Text] [Related]  

  • 13. Pediatric heparin-induced thrombocytopenia: management with Danaparoid (orgaran).
    Saxon BR; Black MD; Edgell D; Noel D; Leaker MT
    Ann Thorac Surg; 1999 Sep; 68(3):1076-8. PubMed ID: 10510017
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Heparin-induced thrombocytopenia type II: perioperative management using danaparoid in a coronary artery bypass patient with renal failure.
    Westphal K; Martens S; Strouhal U; Matheis G; Lindhoff-Last E; Wimmer-Greinecker G; Lischke V
    Thorac Cardiovasc Surg; 1997 Dec; 45(6):318-20. PubMed ID: 9477469
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Heparin-induced thrombopenia during hemodialysis in intensive care: use of a low molecular weight heparinoid, ORG 10172 (Orgaran)].
    Mahul P; Raynaud J; Favre JP; Jospé R; Décousus H; Auboyer C
    Ann Fr Anesth Reanim; 1995; 14(1):29-32. PubMed ID: 7677282
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Danaparoid thromboprophylaxis in pregnant women with heparin-induced thrombocytopenia.
    Woo YL; Allard S; Cohen H; Letsky E; de Swiet M
    BJOG; 2002 Apr; 109(4):466-8. PubMed ID: 12013171
    [No Abstract]   [Full Text] [Related]  

  • 17. Heparin-induced thrombocytopenia type II on hemodialysis: switch to danaparoid.
    Neuhaus TJ; Goetschel P; Schmugge M; Leumann E
    Pediatr Nephrol; 2000 Aug; 14(8-9):713-6. PubMed ID: 10955913
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Danaparoid. A review of its pharmacology and clinical use in the management of heparin-induced thrombocytopenia.
    Wilde MI; Markham A
    Drugs; 1997 Dec; 54(6):903-24. PubMed ID: 9421696
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of danaparoid during cardiopulmonary bypass in patients with heparin-induced thrombocytopenia.
    Olin DA; Urdaneta F; Lobato EB
    J Cardiothorac Vasc Anesth; 2000 Dec; 14(6):707-9. PubMed ID: 11139115
    [No Abstract]   [Full Text] [Related]  

  • 20. [Clinical experience with Danaparoid-sodium: measures to be taken in heparin-induced thrombocytopenia].
    Chirurg; 1998 Nov; 69(11 Suppl Massnahme):1-4. PubMed ID: 9853175
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.